Degeneracy, as opposed to specificity, in immunotherapy.
Hafler
David A
DA
Center for Neurologic Disease, Brigham and Women's Hospital and Harvard Medical School, Harvard Institutes of Medicine, Room 786, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA. dhafler@rics.bwh.harvard.edu
D000818:Animals; D015551:Autoimmunity; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003429:Cross Reactions; D000068717:Glatiramer Acetate; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy; D008024:Ligands; D009103:Multiple Sclerosis / Q000276:immunology; D004676:Myelin Basic Protein / Q000276:immunology; D010455:Peptides / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D008024:Ligands; D004676:Myelin Basic Protein; D010455:Peptides; D011948:Receptors, Antigen, T-Cell; D000068717:Glatiramer Acetate